IN2014CN03250A - - Google Patents

Download PDF

Info

Publication number
IN2014CN03250A
IN2014CN03250A IN3250CHN2014A IN2014CN03250A IN 2014CN03250 A IN2014CN03250 A IN 2014CN03250A IN 3250CHN2014 A IN3250CHN2014 A IN 3250CHN2014A IN 2014CN03250 A IN2014CN03250 A IN 2014CN03250A
Authority
IN
India
Prior art keywords
formula
pyridone
compounds
btk kinase
disorders
Prior art date
Application number
Inventor
James John Crawford
Daniel Fred Ortwine
Binqing Wei
Wendy B Young
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IN2014CN03250A publication Critical patent/IN2014CN03250A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

123 in vitro in situ in vivoHeteroaryl pyridone and aza pyridone compounds of Formula I are provided where one or two of X X and Xare N and including stereoisomers tautomers and pharmaceutically acceptable salts thereof useful for inhibiting Btk kinase and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for and diagnosis and treatment of such disorders in mammalian cells or associated pathological conditions are disclosed.
IN3250CHN2014 2011-11-03 2012-11-02 IN2014CN03250A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161555393P 2011-11-03 2011-11-03
PCT/US2012/063194 WO2013067274A1 (en) 2011-11-03 2012-11-02 Heteroaryl pyridone and aza-pyridone compounds as inhibitors of btk activity

Publications (1)

Publication Number Publication Date
IN2014CN03250A true IN2014CN03250A (en) 2015-07-03

Family

ID=47146779

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3250CHN2014 IN2014CN03250A (en) 2011-11-03 2012-11-02

Country Status (34)

Country Link
US (11) US8716274B2 (en)
EP (5) EP2773638B1 (en)
JP (5) JP5976827B2 (en)
KR (2) KR101659193B1 (en)
CN (2) CN104125959B (en)
AR (2) AR088641A1 (en)
AU (5) AU2012332365B2 (en)
CA (1) CA2853975C (en)
CL (1) CL2014001103A1 (en)
CO (1) CO6950472A2 (en)
CR (1) CR20140194A (en)
CY (1) CY1117097T1 (en)
DK (2) DK3002284T3 (en)
EA (1) EA023263B1 (en)
ES (3) ES2738329T3 (en)
HR (2) HRP20151442T1 (en)
HU (2) HUE028019T2 (en)
IL (1) IL232060A (en)
IN (1) IN2014CN03250A (en)
LT (1) LT3002284T (en)
MA (1) MA35819B1 (en)
MX (2) MX2014005331A (en)
PE (1) PE20141586A1 (en)
PH (1) PH12014500936A1 (en)
PL (3) PL2773638T3 (en)
PT (2) PT3002284T (en)
RS (2) RS54505B1 (en)
SG (1) SG11201401992YA (en)
SI (2) SI2773638T1 (en)
TR (1) TR201909849T4 (en)
TW (4) TWI609868B (en)
UA (1) UA111756C2 (en)
WO (1) WO2013067274A1 (en)
ZA (1) ZA201804727B (en)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014010439A2 (en) * 2011-11-03 2017-04-18 F Hoffmann - La Roche Ag compounds, pharmaceutical composition, production process, method of treating a disease or disorder, methods, kit and use of a pharmaceutical composition
UA111756C2 (en) * 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг HETEROARYLPYRIDONE AND AZAPIRIDONE COMPOUNDS AS BRUTON TYROSINKINASE INHIBITORS
WO2015000949A1 (en) 2013-07-03 2015-01-08 F. Hoffmann-La Roche Ag Heteroaryl pyridone and aza-pyridone amide compounds
WO2015050703A1 (en) * 2013-10-04 2015-04-09 Yi Chen Inhibitors of bruton's tyrosine kinase
EP3077384B1 (en) * 2013-12-05 2017-09-06 F. Hoffmann-La Roche AG Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality
CN106922146B (en) 2014-10-02 2020-05-26 豪夫迈·罗氏有限公司 Pyrazole carboxamide compounds for the treatment of diseases mediated by Bruton's Tyrosine Kinase (BTK)
WO2016066490A1 (en) * 2014-10-27 2016-05-06 F. Hoffmann-La Roche Ag Process for making tricyclic lactam compounds
CN106188063A (en) * 2015-05-08 2016-12-07 中国科学院上海药物研究所 Bicyclic compound used as Lp-PLA2 inhibitor, its preparation method and medical application
HK1249504A1 (en) 2015-09-02 2018-11-02 Glaxosmithkline Intellectual Property (No. 2) Limited Pyridinone dicarboxamide for use as bromodomain inhibitors
EP3365335B1 (en) 2015-10-23 2024-02-14 Array Biopharma, Inc. 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases
AU2017219216B2 (en) * 2016-02-19 2019-12-19 Novartis Ag Tetracyclic pyridone compounds as antivirals
BR112018069530B1 (en) * 2016-02-29 2021-02-17 F. Hoffmann-La Roche Ag dosage form compositions comprising a bruton tyrosine kinase inhibitor
CN108473510B (en) * 2016-04-28 2021-10-29 豪夫迈·罗氏有限公司 Process for the preparation of 2-pyrazolo[1,5-a]pyrazin-2-ylpyrido[1,2-a]pyrimidin-4-one
CN108101905A (en) * 2016-11-24 2018-06-01 中国科学院上海药物研究所 Pyrimido [5,4-b] indolizine or pyrimido [5,4-b] pyrrole biopterin compound, preparation method and the usage
EP3548046A2 (en) 2016-12-03 2019-10-09 Juno Therapeutics, Inc. Methods and compositions for use of therapeutic t cells in combination with kinase inhibitors
JP2020510624A (en) 2016-12-12 2020-04-09 マルチビア インコーポレイテッド Methods and compositions comprising viral gene therapy and immune checkpoint inhibitors for the treatment and prevention of cancer and infectious diseases
AU2017376580B2 (en) 2016-12-15 2020-08-13 F. Hoffmann-La Roche Ag Process for preparing BTK inhibitors
KR102543603B1 (en) 2016-12-22 2023-06-14 베타 파머수티컬 컴퍼니 리미티드 Benzoimidazole derivatives, preparation methods and uses thereof
WO2018175863A1 (en) 2017-03-24 2018-09-27 Genentech, Inc. Methods of treating autoimmune and inflammatory diseases
CN107445981B (en) * 2017-08-25 2018-06-22 牡丹江医学院 A kind of reactive compound for anti-treating cervicitis
KR102613433B1 (en) 2017-10-11 2023-12-13 주식회사 대웅제약 Novel phenyl pyridine derivatives and pharmaceutical composition comprising the same
CN111386272B (en) 2017-10-27 2023-01-06 费森尤斯卡比肿瘤学有限公司 Improved preparation method of Riboxib and salt thereof
MX2020008627A (en) 2018-02-19 2020-09-21 Guangzhou Lupeng Pharmaceutical Company Ltd BTK INHIBITORS AND MUTANTS THEREOF.
TWI801517B (en) 2018-03-12 2023-05-11 加拿大商愛彼特生物製藥公司 Substituted 2-pyridone tricyclic compounds, analogues thereof, and methods using same
WO2019208805A1 (en) 2018-04-27 2019-10-31 小野薬品工業株式会社 PREVENTIVE AND/OR THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASE COMPRISING COMPOUND HAVING Btk INHIBITORY ACTIVITY AS ACTIVE INGREDIENT
WO2019236884A1 (en) 2018-06-07 2019-12-12 Disarm Therapeutics, Inc. Inhibitors of sarm1
CN112424207B (en) 2018-07-25 2024-03-19 诺华股份有限公司 NLRP3 inflammasome inhibitor
KR102328682B1 (en) * 2018-08-27 2021-11-18 주식회사 대웅제약 Novel heterocyclicamine derivatives and pharmaceutical composition comprising the same
WO2020043321A1 (en) 2018-08-31 2020-03-05 Stichting Katholieke Universiteit Synergistic combinations of amino acid depletion agent sensitizers (aadas) and amino acid depletion agents (aada), and therapeutic methods of use thereof
BR112021007115A2 (en) 2018-10-15 2021-07-20 Nurix Therapeutics, Inc. bifunctional compounds for dehydration of btk via the ubiquitin proteosome pathway
CN113474337A (en) 2018-12-19 2021-10-01 奥瑞生物药品公司 7- ((3, 5-dimethoxyphenyl) amino) quinoxaline derivatives as FGFR inhibitors for the treatment of cancer
JP2022515198A (en) 2018-12-19 2022-02-17 アレイ バイオファーマ インコーポレイテッド Substituted pyrazolo [1,5-a] pyridine compound as an inhibitor of FGFR tyrosine kinase
CA3123215C (en) 2018-12-19 2024-04-02 Disarm Therapeutics, Inc. Inhibitors of sarm1 in combination with neuroprotective agents
TW202033523A (en) * 2019-01-17 2020-09-16 美商愛彼特生物製藥股份有限公司 Substituted polycyclic carboxylic acids, analogues thereof, and methods using same
AU2020213265B2 (en) 2019-01-22 2025-01-16 F. Hoffmann-La Roche Ag Methods of treating rheumatoid arthritis, chronic spontaneous urticaria, and systemic lupus erythematosis using an inhibitor of Bruton's tyrosine kinase
EP3930717A1 (en) * 2019-02-25 2022-01-05 Guangzhou Lupeng Pharmaceutical Company Ltd. Inhibitor of btk and mutants thereof
BR112021018168B1 (en) 2019-03-21 2023-11-28 Onxeo PHARMACEUTICAL COMPOSITION, COMBINATION AND KIT COMPRISING A DBAIT MOLECULE AND A KINASE INHIBITOR FOR THE TREATMENT OF CANCER
MX2021012285A (en) 2019-04-09 2021-12-15 Nurix Therapeutics Inc 3-substituted piperidine compounds for cbl-b inhibition, and use of a cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus.
AU2020278592B2 (en) 2019-05-17 2024-10-10 Nurix Therapeutics, Inc. Cyano cyclobutyl compounds for Cbl-b inhibition and uses thereof
UY38687A (en) 2019-05-17 2023-05-15 Novartis Ag NLRP3 INFLAMMASOME INHIBITORS, COMPOSITIONS, COMBINATIONS THEREOF AND METHODS OF USE
MX2021015675A (en) 2019-06-26 2022-02-03 Nurix Therapeutics Inc SUBSTITUTED BENCYL-TRIAZOLE COMPOUNDS FOR THE INHIBITION OF CBL-B AND OTHER USES THEREOF.
WO2021066958A1 (en) 2019-10-05 2021-04-08 Newave Pharmaceutical Inc. Inhibitor of btk and mutants thereof
CA3159348A1 (en) 2019-11-08 2021-05-14 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
US20230024442A1 (en) * 2019-11-08 2023-01-26 Nurix Therapeutics, Inc. Bifunctional compounds for grading btk via ubiquitin proteosome pathway
CA3160713A1 (en) 2019-12-04 2021-06-10 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021164735A1 (en) * 2020-02-20 2021-08-26 Hutchison Medipharma Limited Heteroaryl heterocyclic compounds and uses thereof
TWI899163B (en) 2020-02-28 2025-10-01 美商建南德克公司 Methods of treating primary progressive multiple sclerosis using an inhibitor of bruton's tyrosine kinase
TWI907406B (en) 2020-04-03 2025-12-11 美商建南德克公司 Methods of treating relapsing multiple sclerosis using an inhibitor of bruton's tyrosine kinase
US20230348471A1 (en) * 2020-06-18 2023-11-02 Shanghai Synergy Pharmaceutical Sciences Co., Ltd. Bruton's tyrosine kinase inhibitor and preparation method therefor
WO2022029068A1 (en) * 2020-08-04 2022-02-10 F. Hoffmann-La Roche Ag Pyridinone compounds for the treatment of autoimmune disease
MX2023001865A (en) * 2020-08-14 2023-05-09 Guangzhou Lupeng Pharmaceutical Company Ltd DOSAGE FORM COMPOSITIONS COMPRISING A BTK INHIBITOR AND MUTANTS THEREOF.
EP4196478A1 (en) 2020-08-14 2023-06-21 Novartis AG Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof
EP4214206A4 (en) 2020-09-21 2024-10-09 Hutchison Medipharma Limited HETEROCYCLIC HETEROARYL COMPOUNDS AND THEIR USES
WO2022094172A2 (en) 2020-10-30 2022-05-05 Newave Pharmaceutical Inc. Inhibitors of btk
US20240058457A1 (en) 2020-12-20 2024-02-22 Newave Pharmaceutical Inc. Btk degrader
US20240216330A1 (en) * 2021-04-02 2024-07-04 Biogen Ma Inc. Combination treatment methods of multiple sclerosis
AU2022254104A1 (en) 2021-04-08 2023-10-26 Nurix Therapeutics, Inc. Combination therapies with cbl-b inhibitor compounds
IL307819A (en) 2021-05-05 2023-12-01 Hoffmann La Roche BTK inhibitor preparation process
CN113603685A (en) * 2021-07-23 2021-11-05 都创(上海)医药开发有限公司 Crystal form of Fenebbrutinib compound, preparation method and application thereof
KR20240090898A (en) 2021-10-26 2024-06-21 누릭스 테라퓨틱스 인코포레이티드 Piperidinylpyrazine-carboxamide compound to treat and prevent cancer and degrade BTK
US20250074911A1 (en) 2021-12-14 2025-03-06 Crossfire Oncology Holding B.V. Macrocyclic btk inhibitors
US20250136620A1 (en) * 2022-01-17 2025-05-01 Newave Pharmaceutical Inc. Btk degrader
TW202346276A (en) 2022-01-27 2023-12-01 日商田邊三菱製藥股份有限公司 Novel b0at1 inhibitor
US20250154155A1 (en) * 2022-01-28 2025-05-15 Hutchmed Limited Synthetic method of 7,8-dihydro-2h-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6h)-one compounds
UY40374A (en) 2022-08-03 2024-02-15 Novartis Ag NLRP3 INFLAMASOME INHIBITORS
CN121100112A (en) 2023-04-06 2025-12-09 田边三菱制药株式会社 Novel B0AT1 inhibitors
IL324509A (en) 2023-05-16 2026-01-01 Genentech Inc Methods of treating relapsing multiple sclerosis using an inhibitor of bruton's tyrosine kinase
WO2024246287A1 (en) 2023-06-02 2024-12-05 Crossfire Oncology Holding B.V. Medical use of a macrocyclic reversible btk inhibitor
WO2024245578A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a macrocyclic reversible btk inhibitor
WO2024245577A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a reversible btk inhibitor
WO2024256574A1 (en) 2023-06-13 2024-12-19 Crossfire Oncology Holding B.V. Process for preparing macrocyclic btk inhibitors
WO2024256568A1 (en) 2023-06-13 2024-12-19 Crossfire Oncology Holding B.V. Salt and crystal forms of a macrocyclic btk inhibitor
AU2024320769A1 (en) * 2023-08-07 2026-03-05 Guangzhou Lupeng Pharmaceutical Co., Ltd. Crystal form vi of acrylamide compound, and preparation method therefor and use thereof
WO2026017823A1 (en) 2024-07-18 2026-01-22 F. Hoffmann-La Roche Ag Process for preparing btk inhibitor intermediates

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5583024A (en) 1985-12-02 1996-12-10 The Regents Of The University Of California Recombinant expression of Coleoptera luciferase
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
JPH08336393A (en) 1995-04-13 1996-12-24 Mitsubishi Chem Corp Process for producing optically active γ-substituted-β-hydroxybutyric acid ester
US6602677B1 (en) 1997-09-19 2003-08-05 Promega Corporation Thermostable luciferases and methods of production
CN100528329C (en) 2001-07-12 2009-08-19 里艾克沙有限公司 Microencapsulated catalysts, methods of their preparation and methods of use
US7405295B2 (en) 2003-06-04 2008-07-29 Cgi Pharmaceuticals, Inc. Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
WO2005005429A1 (en) 2003-06-30 2005-01-20 Cellular Genomics, Inc. Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds
EP2457895A1 (en) 2004-07-12 2012-05-30 Idun Pharmaceuticals, Inc. Tetrapeptide analogs
EP1812442A2 (en) 2004-11-10 2007-08-01 CGI Pharmaceuticals, Inc. Imidazo[1,2-a]pyrazin-8-ylamines useful as modulators of kinase activity
MX2007011041A (en) 2005-03-10 2008-02-22 Cgi Pharmaceuticals Inc Certain substituted amides, method of making, and method of use thereof.
DE602006021205D1 (en) 2005-10-07 2011-05-19 Exelixis Inc AZETIDINES AS MEK INHIBITORS IN THE TREATMENT OF PROLIFERATIVE DISEASES
US7838523B2 (en) 2006-09-11 2010-11-23 Cgi Pharmaceuticals, Inc. Certain substituted amides, method of making, and method of use thereof
AR063706A1 (en) 2006-09-11 2009-02-11 Cgi Pharmaceuticals Inc CERTAIN AMIDAS REPLACED, THE USE OF THE SAME FOR THE TREATMENT OF DISEASES MEDIATED BY THE INHIBITION OF THE ACTIVITY OF BTK AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM.
AR063946A1 (en) 2006-09-11 2009-03-04 Cgi Pharmaceuticals Inc CERTAIN REPLACED PIRIMIDINS, THE USE OF THE SAME FOR THE TREATMENT OF DISEASES MEDIATED BY THE INHIBITION OF THE ACTIVITY OF BTK AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM.
EA018573B1 (en) * 2006-09-22 2013-09-30 Фармасайкликс, Инк. BLUTON TYROSINKINASE INHIBITORS
CL2008002793A1 (en) 2007-09-20 2009-09-04 Cgi Pharmaceuticals Inc Compounds derived from substituted amides, inhibitors of btk activity; pharmaceutical composition comprising them; Useful in the treatment of cancer, bone disorders, autoimmune diseases, among others
EP2205564B1 (en) * 2007-10-23 2014-07-30 F. Hoffmann-La Roche AG Novel kinase inhibitors
US8426441B2 (en) 2007-12-14 2013-04-23 Roche Palo Alto Llc Inhibitors of bruton's tyrosine kinase
WO2009098144A1 (en) * 2008-02-05 2009-08-13 F. Hoffmann-La Roche Ag Novel pyridinones and pyridazinones
US7683064B2 (en) 2008-02-05 2010-03-23 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
US8426424B2 (en) 2008-05-06 2013-04-23 Cgi Pharmaceuticals, Inc. Certain substituted amides, method of making, and method of use thereof
WO2009156284A1 (en) 2008-06-24 2009-12-30 F. Hoffmann-La Roche Ag Novel substituted pyridin-2-ones and pyridazin-3-ones
AU2009265813B2 (en) 2008-07-02 2014-04-10 F. Hoffmann-La Roche Ag Novel phenylpyrazinones as kinase inhibitors
CA2636807A1 (en) 2008-07-04 2010-01-04 Steven Splinter Methods for obtaining cyclopamine
EP2307413B1 (en) 2008-07-15 2015-09-09 F. Hoffmann-La Roche AG Novel phenyl-imidazopyridines and pyridazines
US8598174B2 (en) 2008-11-12 2013-12-03 Genetech, Inc. Pyridazinones, method of making, and method of use thereof
US8299077B2 (en) 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
CA2748414A1 (en) * 2009-04-24 2010-10-28 F. Hoffmann-La Roche Ag Inhibitors of bruton's tyrosine kinase
JP5656976B2 (en) * 2009-04-29 2015-01-21 ローカス ファーマシューティカルズ インコーポレイテッド Pyrrolotriazine compounds
CA2771822C (en) * 2009-09-04 2020-08-11 Daniel A. Erlanson Bruton's tyrosine kinase inhibitors
CN110818724B (en) * 2010-05-07 2020-11-13 吉利德康涅狄格有限公司 Pyridone and azapyridone compounds and methods of use
AR082590A1 (en) 2010-08-12 2012-12-19 Hoffmann La Roche INHIBITORS OF THE TIROSINA-QUINASA DE BRUTON
JP5842004B2 (en) 2010-09-01 2016-01-13 ジーアイリード コネチカット インコーポレーテッドＧｉｌｅａｄ Ｃｏｎｎｅｃｔｉｃｕｔ，Ｉｎｃ． Pyridazinone, its production method and its use
US9249123B2 (en) 2010-09-01 2016-02-02 Genentech, Inc. Pyridinones/pyrazinones, method of making, and method of use thereof
CA2834077A1 (en) 2011-05-17 2012-11-22 F. Hoffmann-La Roche Ag Inhibitors of bruton's tyrosine kinase
BR112014003582A2 (en) 2011-08-17 2017-03-14 Hoffmann La Roche bruton tyrosine kinase inhibitors
RU2622391C2 (en) * 2011-11-03 2017-06-15 Ф. Хоффманн-Ля Рош Аг Compound 8-fluorophthalazine-1(2h)-one as inhibitors of bruton tyrosine kinase
UA111756C2 (en) * 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг HETEROARYLPYRIDONE AND AZAPIRIDONE COMPOUNDS AS BRUTON TYROSINKINASE INHIBITORS
BR112014010439A2 (en) 2011-11-03 2017-04-18 F Hoffmann - La Roche Ag compounds, pharmaceutical composition, production process, method of treating a disease or disorder, methods, kit and use of a pharmaceutical composition
WO2015000949A1 (en) * 2013-07-03 2015-01-08 F. Hoffmann-La Roche Ag Heteroaryl pyridone and aza-pyridone amide compounds
EP3077384B1 (en) * 2013-12-05 2017-09-06 F. Hoffmann-La Roche AG Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality
BR112018069530B1 (en) * 2016-02-29 2021-02-17 F. Hoffmann-La Roche Ag dosage form compositions comprising a bruton tyrosine kinase inhibitor

Also Published As

Publication number Publication date
PL2773638T3 (en) 2016-03-31
EA201490858A1 (en) 2014-08-29
HK1201265A1 (en) 2015-08-28
SG11201401992YA (en) 2014-05-29
CO6950472A2 (en) 2014-05-20
US20140194408A1 (en) 2014-07-10
RS59016B1 (en) 2019-08-30
ES2738329T3 (en) 2020-01-22
CR20140194A (en) 2014-06-03
US8716274B2 (en) 2014-05-06
AU2020202707A1 (en) 2020-05-14
IL232060A (en) 2016-02-29
DK2773638T3 (en) 2015-10-19
US8921353B2 (en) 2014-12-30
US20160228432A1 (en) 2016-08-11
KR20140096097A (en) 2014-08-04
JP2018080193A (en) 2018-05-24
US9238655B2 (en) 2016-01-19
JP2019108342A (en) 2019-07-04
US20240270747A1 (en) 2024-08-15
AU2018201557A1 (en) 2018-03-22
AU2016273930A1 (en) 2017-01-12
BR112014010459A2 (en) 2017-04-18
DK3002284T3 (en) 2019-07-29
EP4050012A1 (en) 2022-08-31
HUE028019T2 (en) 2016-11-28
JP2016028046A (en) 2016-02-25
ZA201804727B (en) 2023-03-29
JP2020183397A (en) 2020-11-12
TW201326175A (en) 2013-07-01
KR20160003328A (en) 2016-01-08
US10045983B2 (en) 2018-08-14
TW202124384A (en) 2021-07-01
IL232060A0 (en) 2014-05-28
MX361807B (en) 2018-12-17
AR088641A1 (en) 2014-06-25
AU2012332365B2 (en) 2016-09-15
US20140378432A1 (en) 2014-12-25
AU2016273930B2 (en) 2018-03-08
MA35819B1 (en) 2014-12-01
US20230279012A1 (en) 2023-09-07
PT3002284T (en) 2019-07-17
AU2020202707B2 (en) 2021-09-02
PH12014500936A1 (en) 2014-06-09
WO2013067274A1 (en) 2013-05-10
EP3521288A1 (en) 2019-08-07
EP3521288B1 (en) 2021-09-08
US9782405B2 (en) 2017-10-10
TR201909849T4 (en) 2019-07-22
PE20141586A1 (en) 2014-10-25
CY1117097T1 (en) 2017-04-05
PT2773638E (en) 2016-01-12
US20190194203A1 (en) 2019-06-27
CN104125959B (en) 2017-05-03
AU2019216728A1 (en) 2019-09-05
ES2898938T3 (en) 2022-03-09
CA2853975A1 (en) 2013-05-10
ES2555168T3 (en) 2015-12-29
TWI652270B (en) 2019-03-01
EP4019508A1 (en) 2022-06-29
RS54505B1 (en) 2016-06-30
AU2012332365A1 (en) 2014-05-01
EP2773638B1 (en) 2015-10-07
TWI609868B (en) 2018-01-01
SI2773638T1 (en) 2015-12-31
AU2019216728B2 (en) 2020-04-09
US20200062769A1 (en) 2020-02-27
US20130116235A1 (en) 2013-05-09
US20180071286A1 (en) 2018-03-15
HRP20191307T1 (en) 2019-10-18
LT3002284T (en) 2019-08-12
JP6571215B2 (en) 2019-09-04
TW201741315A (en) 2017-12-01
CA2853975C (en) 2020-02-25
AU2018201557B2 (en) 2019-09-19
TW201906845A (en) 2019-02-16
JP5976827B2 (en) 2016-08-24
NZ624021A (en) 2016-09-30
PL3521288T3 (en) 2021-12-27
US20210079002A1 (en) 2021-03-18
EA023263B1 (en) 2016-05-31
SI3002284T1 (en) 2019-08-30
CL2014001103A1 (en) 2014-10-03
USRE48239E1 (en) 2020-10-06
TWI701250B (en) 2020-08-11
KR101659193B1 (en) 2016-09-22
EP3002284A1 (en) 2016-04-06
AR117501A2 (en) 2021-08-11
CN107011348B (en) 2020-01-10
HRP20151442T1 (en) 2016-01-29
UA111756C2 (en) 2016-06-10
PL3002284T3 (en) 2019-11-29
JP2014532762A (en) 2014-12-08
CN104125959A (en) 2014-10-29
CN107011348A (en) 2017-08-04
EP3002284B1 (en) 2019-05-22
HUE044959T2 (en) 2019-12-30
MX2014005331A (en) 2014-05-28
EP2773638A1 (en) 2014-09-10

Similar Documents

Publication Publication Date Title
IN2014CN03250A (en)
MY160349A (en) Pyridone and aza-pyridone compounds and methods of use
IN2014CN03265A (en)
MX2014005285A (en) Bicyclic piperazine compounds.
MX2014005282A (en) 8-fluorophthalazin-1 (2h) - one compounds as inhibitors of btk activity.
MX2016007171A (en) Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality.
MX2015018038A (en) Heteroaryl pyridone and aza-pyridone amide compounds.
MX355852B (en) PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE.
MX2014014828A (en) 5-azaindazole compounds and methods of use.
PH12015500488A1 (en) Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
MX340013B (en) Benzoxazepin compounds selective for pi3k p110 delta and methods of use.
PH12012501864A1 (en) Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
BR112013020329A2 (en) heterocyclic compounds as pi3 kinase inhibitors
PH12013502445A1 (en) Pyridin-2 (1h) -one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
MX350112B (en) Furo [3, 2 - b] - and thieno [3, 2 - b] pyridine derivatives as tbk1 and ikk inhibitors.
PH12014501829A1 (en) Bicyclic pyrazinone derivatives
SG10201805392YA (en) 1,2,4-triazine-6-carboxamide kinase inhibitors
MX362855B (en) Quinazolinone derivatives as parp inhibitors.
MX345127B (en) Thiazole derivatives.
PH12015500063A1 (en) Azaindole derivatives which act as pi3k inhibitors
IN2014CN04065A (en)
MY166463A (en) Positive allosteric modulators of nicotinic acetylcholine receptor
MX2016012007A (en) Oxepan-2-yl-pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use.
NZ620928A (en) Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
MA42864B1 (en) Cyclic ether-pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use